Literature DB >> 15857980

Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies.

Krystyna Mozdzanowska1, Michelle Furchner, Darya Zharikova, Jingqi Feng, Walter Gerhard.   

Abstract

Previous studies have indicated that B cells make a significant contribution to the resolution of influenza virus infection. To determine how B cells participate in the control of the infection, we transferred intact, major histocompatibility complex class II (MHC-II)-negative or B-cell receptor (BCR)-transgenic spleen cells into B-cell-deficient and CD8(+) T-cell-depleted muMT mice, termed muMT(-8), and tested them for ability to recover from infection. muMT(-8) mice that received no spleen cells invariably succumbed to the infection within 20 days, indicating that CD4(+) T-cell activities had no significant therapeutic activity on their own; in fact, they were harmful and decreased survival time. Interestingly, however, they became beneficial in the presence of antiviral antibody (Ab). Injection of MHC-II((-/-)) spleen cells, which can provide CD4(+) T-cell-independent (TI) but not T-cell-dependent (TD) activities, delayed mortality but only rarely resulted in clearance of the infection. By contrast, 80% of muMT(-8) mice injected with normal spleen cells survived and resolved the infection. Transfer of BCR-transgenic spleen cells, which contained approximately 10 times fewer virus-specific precursor B cells than normal spleen cells, had no significant impact on the course of the infection. Taken together, the results suggest that B cells contribute to the control of the infection mainly through production of virus-specific Abs and that the TD Ab response is therapeutically more effective than the TI response. In addition, CD4(+) T cells appear to contribute, apart from promoting the TD Ab response, by improving the therapeutic activity of Ab-mediated effector mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857980      PMCID: PMC1091716          DOI: 10.1128/JVI.79.10.5943-5951.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  Organogenic role of B lymphocytes in mucosal immunity.

Authors:  T V Golovkina; M Shlomchik; L Hannum; A Chervonsky
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

2.  CD4+ T cells derived from B cell-deficient mice inhibit the establishment of peripheral B cell pools.

Authors:  N Baumgarth; G C Jager; O C Herman; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

3.  Diminished primary and secondary influenza virus-specific CD8(+) T-cell responses in CD4-depleted Ig(-/-) mice.

Authors:  J M Riberdy; J P Christensen; K Branum; P C Doherty
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon.

Authors:  X Wang; M Li; H Zheng; T Muster; P Palese; A A Beg; A García-Sastre
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes.

Authors:  H H Nguyen; H L Vu; J R McGhee; J Mestecky
Journal:  J Infect Dis       Date:  2000-12-20       Impact factor: 5.226

6.  Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication.

Authors:  M Bergmann; A Garcia-Sastre; E Carnero; H Pehamberger; K Wolff; P Palese; T Muster
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice.

Authors:  G E Price; A Gaszewska-Mastarlarz; D Moskophidis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

8.  Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.

Authors:  T M Tumpey; M Renshaw; J D Clements; J M Katz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection.

Authors:  N Baumgarth; O C Herman; G C Jager; L E Brown; L A Herzenberg; J Chen
Journal:  J Exp Med       Date:  2000-07-17       Impact factor: 14.307

10.  Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system.

Authors:  D C Hooper; K Morimoto; M Bette; E Weihe; H Koprowski; B Dietzschold
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

View more
  34 in total

Review 1.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

Review 2.  Protective B cell responses to flu--no fluke!

Authors:  Elizabeth E Waffarn; Nicole Baumgarth
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

3.  Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Authors:  Shannon L Haley; Evgeni P Tzvetkov; Samantha Meuwissen; Joseph R Plummer; James P McGettigan
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

4.  Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.

Authors:  Christopher R Lupfer; Kate L Stokes; Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

5.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

6.  Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF.

Authors:  Weifeng Xu; Paul A Santini; Allysia J Matthews; April Chiu; Alessandro Plebani; Bing He; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

7.  Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.

Authors:  Michelle Roti; Junbao Yang; DeAnna Berger; Laurie Huston; Eddie A James; William W Kwok
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

8.  B-cell fate decisions following influenza virus infection.

Authors:  Kristina Rothaeusler; Nicole Baumgarth
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

9.  Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection.

Authors:  David Verhoeven; John R Teijaro; Donna L Farber
Journal:  Virology       Date:  2009-06-02       Impact factor: 3.616

10.  Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines.

Authors:  Paul Thiamjoo Tan; A T Heiny; Olivo Miotto; Jerome Salmon; Ernesto T A Marques; Francois Lemonnier; J Thomas August
Journal:  PLoS One       Date:  2010-01-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.